Nova Patents
AT488581T

FACTOR VII OR VIIa POLYPEPTIDE VARIANTS

Abstract

The invention relates to clotting factor VII (FVII) or clotting factor VIIa (FVIIa) is new polypeptide variant thereof, wherein the variant comprises the amino acid substitution of 10th and seq, wherein the variant further comprises a and component, comprising a position introducing the inner n-glycosylated is covalently wherein Gla domain is connected. The polypeptide variant can be used for treating, and is used to treat more and hemoglutination the related disease, to a wound.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Granted
  4. Today

35 members in 21 offices

This recordMember, by publication datePriority claim11 more offices are in the list below

Priority claims2

Priority claims
DocumentOfficeKindDate
37667902United States of AmericaP
0300276DenmarkW

Members35

Family members, oldest first
DocumentOfficeKind
CA2483478A1CanadaA1
WO03093465A1World Intellectual Property Organization (WIPO)A1
AU2003221469A1AustraliaA1
KR20040106424ARepublic of KoreaA
EP1499719A1European Patent Office (EPO)A1
BR0309576ABrazilA
MXPA04010781AMexicoA
RU2004134726ARussian FederationA
JP2005523723AJapanA
PL373728A1PolandA1
CN1665925AChinaA
ZA200409475BSouth AfricaB
IL164764A0IsraelA0
US2006111282A1United States of AmericaA1
NZ536340ANew ZealandA
US2006270000A1United States of AmericaA1
US2006270001A1United States of AmericaA1
US2006270002A1United States of AmericaA1
US2006276377A1United States of AmericaA1
AU2008261165A1AustraliaA1
US7700733B2United States of AmericaB2
JP2010213706AJapanA
US2010260741A1United States of AmericaA1
EP1499719B1European Patent Office (EPO)B1
AT488581TThis recordAustriaT
ATE488581T1AustriaT1
DE60334983D1GermanyD1
CN101942019AChinaA
PT1499719EPortugalE
DK1499719T3DenmarkT3
ES2355713T3SpainT3
SI1499719T1SloveniaT1
KR101121593B1Republic of KoreaB1
IL164764AIsraelA
US9353365B2United States of AmericaB2